Navigation Links
Isis Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
Date:9/4/2013

CARLSBAD, Calif., Sept. 4, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2013 at 2:05 p.m. ET in New York, NY.

(Logo:  http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's website, www.isispharm.com.  A replay will be available on the Isis website within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 29 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

Forward-Looking Statements
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.  In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
2. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
4. Clinical Trials, New Orders, Improved Services, and Approvals - Research Report on CareFusion, St. Jude Medical, Community Health Systems, Neurocrine Biosciences, and Alnylam Pharmaceuticals
5. DelMar Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference
6. Inovio Pharmaceuticals to Present at Upcoming Investor Conferences
7. Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data
8. AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
9. Alexza Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
10. Edison expands North American healthcare sector coverage with initiation of coverage on Alexza Pharmaceuticals
11. Imprimis Pharmaceuticals, Inc. Acquires Intellectual Property for Ophthalmic Compound Development Opportunity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... , July 26, 2017 The Galien Foundation ... Galien USA Award Nominees. Counted among ... Galien Award recognizes outstanding biomedical and technology product achievement that ... To qualify, each candidate must be U.S. Food and ... years and demonstrate tremendous potential to impact human health. Sales ...
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized as a ... for the fourth year in a row. 1 ... the Leaders quadrant have the highest scores for their Ability ... Leaders quadrant has the market share, credibility, and marketing and ... These vendors demonstrate a clear understanding of market needs; they ...
(Date:7/21/2017)... SPRING, Md. and RESEARCH TRIANGLE ... United Therapeutics Corporation (NASDAQ: UTHR ) announced ... financial results before the market opens on Thursday, July ... Therapeutics will host a teleconference on Thursday, July 27, ... accessible by dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with Six ... schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing patients ... will bring more Six Month Smiles patients to their providers.” , Each month, over ...
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care ... the treatment program located in Royal Oak, Michigan. IDC, formerly known as ... focused on providing the highest standards in the field of eating disorder treatment in ...
(Date:7/26/2017)... ... July 26, 2017 , ... The Amnesty Rally 2017 will be held on ... 3313 Bernstein Park Drive in Monroe (adjacent to the Louisiana Purchase Gardens & Zoo). ... gun violence throughout Monroe. Citizens can turn in unregistered, illegally-held and imitation guns to ...
(Date:7/26/2017)... ... July 26, 2017 , ... BioPlus Specialty Pharmacy ... updated version of the HCV Treatment Path app (version 4.4.0) to keep health ... (HCV) infection. All of the latest HCV medications are included in this app, ...
(Date:7/25/2017)... ... July 25, 2017 , ... “Now Hiring!” is a popular phrase at ... company has achieved record-breaking sales for over 30 consecutive years and now plans to ... The upcoming year offers excitement and growth at HDIS, following the company’s acquisition by ...
Breaking Medicine News(10 mins):